Feb 9, 2026 10:04 am EST Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 31, 2025 7:30 am EST Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 15, 2025 7:30 am EST Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
Dec 11, 2025 7:30 am EST Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
Dec 8, 2025 7:30 am EST Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
Dec 1, 2025 7:30 am EST Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 12, 2025 7:30 am EST Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
Nov 7, 2025 7:30 am EST Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
Nov 3, 2025 7:30 am EST Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 30, 2025 10:45 am EDT Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
